IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
Hu, Yunfei1,2; Ding, Ning1; Jin, Xuan3; Feng, Lixia1; Ping, Lingyan1; Song, Yuqin1; Zhu, Jun1
关键词Diffuse large B-cell lymphoma STAT3 Single nucleotide polymorphism Rituximab
刊名CANCER CELL INTERNATIONAL
2014-03-13
DOI10.1186/1475-2867-14-25
14
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]ANTI-CD20 MONOCLONAL-ANTIBODY ; CHRONIC LYMPHOCYTIC-LEUKEMIA ; NON-HODGKINS-LYMPHOMA ; SIGNALING PATHWAY ; INTERFERON-ALPHA ; R-CHOP ; CANCER ; ACTIVATION ; SURVIVAL ; INHIBITION
英文摘要

Background: Rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL). Inactivation of phosphorylation of STAT3 plays an essential role in rituximab-induced anti-proliferative activity in B-cell lymphoma. However, the relationship between STAT3 genetic polymorphisms and clinical response to standard frontline treatment with rituximab has not been well illustrated yet.

Methods: In this study we analyzed the STAT3 polymorphisms and prognosis of 166 diffuse large B-cell lymphoma (DLBCL) patients who were treated with rituximab from 2007 to 2010. Determination of the STAT3 polymorphisms of rs2293152 from genomic DNA was achieved by Sanger chain termination sequencing.

Results: We did not observe obvious correlation between patients′ disease features and STAT3 polymorphisms, but patients with homozygous genotypes at rs2293162 showed a trend of higher CR rate than those with the heterozygous genotype, especially in non-GCB subgroup (p = 0.011). Furthermore, homozygous genotypes GG and CC also showed advantages of long-term survival compared with heterozygous genotype patients (p = 0.022).

Conclusions: These results suggest that STAT3 polymorphisms could be a suitable biomarker related to clinical outcome of DLBCL patients treated with rituximab.

语种英语
WOS记录号WOS:000334623400001
项目编号81201873 ; 81241073 ; 7132050
资助机构NSFC ; Beijing Natural Science Foundation ; Peking University
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65131
专题北京大学临床肿瘤学院_淋巴肿瘤内科
北京大学第一临床医学院_肿瘤化疗科
作者单位1.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Guizhou Canc Hosp, Guiyang Med Coll, Affiliated Hosp, Dept Oncol, Guiyang 550003, Peoples R China
3.Peking Univ, Hosp 1, Dept Internal Med Oncol, Beijing 100034, Peoples R China
推荐引用方式
GB/T 7714
Hu, Yunfei,Ding, Ning,Jin, Xuan,et al. Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab[J]. CANCER CELL INTERNATIONAL,2014,14.
APA Hu, Yunfei.,Ding, Ning.,Jin, Xuan.,Feng, Lixia.,Ping, Lingyan.,...&Zhu, Jun.(2014).Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.CANCER CELL INTERNATIONAL,14.
MLA Hu, Yunfei,et al."Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab".CANCER CELL INTERNATIONAL 14(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hu, Yunfei]的文章
[Ding, Ning]的文章
[Jin, Xuan]的文章
百度学术
百度学术中相似的文章
[Hu, Yunfei]的文章
[Ding, Ning]的文章
[Jin, Xuan]的文章
必应学术
必应学术中相似的文章
[Hu, Yunfei]的文章
[Ding, Ning]的文章
[Jin, Xuan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。